ReviewCurrent treatment options in oncology2019
Diagnosis and Treatment of Breast Cancer in Young Women.
Review in Current treatment options in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mortality of Young Women due to Breast Cancer in Low, Middle and High-Income Countries: Systematic Literature Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- The Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients With Breast Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Factors influencing fear of cancer recurrence in breast cancer survivors: a multicenter cross-sectional study.BMC women's health · 2026Article
- SALL4-targeted therapeutic peptide PEN-FFW suppresses PD-L1 and enhances CD8⁺ T cell cytotoxicity via regulating PI3K/AKT signaling in breast cancer.Immunologic research · 2026Article
- Ultrasound viscosity imaging empowers BI-RADS: toward precise breast lesion diagnosis and analysis of HER2 status.Frontiers in oncology · 2026Article
- Fertility preservation and reproductive outcomes in young women with breast and gynecological cancers: a new challenge for the clinician.Frontiers in oncology · 2026Review
- Article
- Diagnosis and treatment of breast cancer during pregnancy: a comprehensive review.Frontiers in medicine · 2026Review
- Management and treatment of breast cancer in pregnant women.Archives of medical science : AMS · 2026Article
- Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma.Frontiers in oncology · 2026Article
- Poor Prognostic Clinicopathological Features of Young Women with Breast Cancer in the MF18-04 Turkish National Breast Cancer Registry Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Article
- Breast Cancer Treatments: Drugs Targeting the PI3K/AKT/mTOR Pathway, TNBC Therapy and Future Directions: A Review.Life (Basel, Switzerland) · 2025Review
- LRRC75A-AS1 facilitates breast cancer cell proliferation and invasion via functioning as a CeRNA to modulate miR489-3p/ARD1.Scientific reports · 2025Article
- Lactate and lactylation in breast cancer: current understanding and therapeutic opportunities.Cancer biology & medicine · 2025Review
- A Descriptive Phenomenological Study of the Women's Experiences From the Suspicion of Breast Cancer to the Initiation of Treatment.Scandinavian journal of caring sciences · 2025Article
- Effect of inhalational agents in breast cancer surgery on tumour metastasis: Systematic review and meta-analysis.Indian journal of anaesthesia · 2025Article
- Development and validation of a screening model for benign and malignant breast masses based on S-Detect and microvascular flow imaging.Gland surgery · 2025Article
- Use of machine learning algorithms to construct models of symptom burden cluster risk in breast cancer patients undergoing chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy.Scientific reports · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementDespite the increase of breast cancer incidence with age, approximately 7 to 10% ofwomen diagnosed with breast cancer are younger than the age 40. This subgroup ofpatients has different risk factors, tumour biology, clinical outcomes, and specific psy- chosocial issues, such as fertility preservation, family planning, and job reintegration. However, age alone should not be the main consideration when choosing the aggressive- ness of the treatment, as other factors must be considered, including the biologic aggressiveness of the tumour, potential long-term toxicities, and the preferences of the patient. Fertility preservation techniques should be discussed with the patient before starting any cancer treatment. Despite the significant percentage of breast cancer patients younger than age 40, fewclinical studies have specifically investigated disease characteristics and outcomes of this population, and most therapies routinely administered to these younger women were tested in older patients. Moreover, young women who have breast cancer are at a greater risk of sexual and psychological distress, and clinicians should address these issues in order to properly support patients during the long diagnostic and therapeutic journey. Consequently, it is essential to follow diagnostic and treatment guidelines specificallyaddressed to young women. Additional specific procedures should be followed to treat pregnant patients with breast cancer.
Indexed as
Identifiers
31776799What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.